Lipids in Alzheimer's disease: A century-old story

Foley, Paul

doi:10.1016/j.bbalip.2010.05.004

Cited by 138 publications

(104 citation statements)

References 10 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Brains with AD display a higher occurrence of “adipose inclusions” or “lipoid granules”, suggesting aberrant lipid metabolism (Foley, 2010). In the brain, cholesterol is present mainly in its unesterified form in myelin sheaths and the cellular membranes of glial cells and neurons (Dietschy & Turley, 2001).…”

Section: Lifestyle Associations and Interventions For Aging And Admentioning

confidence: 99%

Aging and Alzheimer’s disease: Comparison and associations from molecular to system level

et al. 2018

View full text Add to dashboard Cite

Alzheimer's disease is the most prevalent cause of dementia, which is defined by the combined presence of amyloid and tau, but researchers are gradually moving away from the simple assumption of linear causality proposed by the original amyloid hypothesis. Aging is the main risk factor for Alzheimer's disease that cannot be explained by amyloid hypothesis. To evaluate how aging and Alzheimer's disease are intrinsically interwoven with each other, we review and summarize evidence from molecular, cellular, and system level. In particular, we focus on study designs, treatments, or interventions in Alzheimer's disease that could also be insightful in aging and vice versa.

show abstract

Section: Lifestyle Associations and Interventions For Aging And Admentioning

confidence: 99%

Aging and Alzheimer’s disease: Comparison and associations from molecular to system level

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Indeed, studies investigating the role of lipids in the brain have revealed abnormal lipid metabolism as an important pathophysiological process in the development of AD. 75,76 Diets consisting of an increased consumption of saturated and trans-fats incur an increased incidence of AD, while diets rich in healthy fats are protective. 72,77 Excess saturated fat intake increases circulating lipids, including FFAs, and inflammatory cytokines and requires a redistribution of the lipid content within cells.…”

Section: Dyslipidemiamentioning

confidence: 99%

Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease

Salameh

Rhea

Banks

et al. 2016

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

An increased risk for Alzheimer's disease is associated with dyslipidemia and insulin resistance. A separate literature shows the genetic risk for developing Alzheimer's disease is strongly correlated to the presence of the E4 isoform of the apolipoprotein E carrier protein. Understanding how apolipoprotein E carrier protein, lipids, amyloid b peptides, glucose, central nervous system insulin, and peripheral insulin interact with one another in Alzheimer's disease is an area of increasing interest. Here, we will review the evidence relating apolipoprotein E carrier protein, lipids, and insulin action to Alzheimer's disease and Ab peptides and then propose mechanisms as to how these factors might interact with one another to impair cognition and promote Alzheimer's disease.

show abstract

“…Alteration in AD lipid metabolism has been suggested since brain tissue from AD patients display a higher occurrence of "adipose inclusions" or "lipoid granules", already observed by Alois Alzheimer when he first described the disease [125]. In fact, a close link between lipid metabolism and AD has been established when the ɛ4 allele of the apolipoprotein E (ApoE) gene was identified as the strongest genetic risk factor for AD [126,127].…”

Section: Metabolomics and Ad In Plasma And Serummentioning

confidence: 98%

Metabolomics in the Study of Alzheimer's Disease

Ibáñez

Valdés

García‐Cañas

et al. 2014

Comprehensive Analytical Chemistry

View full text Add to dashboard Cite

With an increasing aging population, Alzheimer's disease (AD) has become a social and economic problem to societies worldwide, affecting millions of people. However, pathophysiological events associated with AD are not well elucidated yet and current definitive diagnosis is only obtained after death through examination of brain tissue. In the last years, Metabolomics has been demonstrated to provide deep insights into the full complexity of the disease phenotype and has been established as a promising approach to provide disease-specific metabolite signatures. The incipient application of Metabolomics may potentially contribute in the elucidation of AD physiopathological processes and ideally may offer therapeutic/preventing mechanisms to slow or reverse AD progress. In this chapter non-targeted metabolomics approaches applied to AD investigation are described.

show abstract

Lipids in Alzheimer's disease: A century-old story

Cited by 138 publications

References 10 publications

Aging and Alzheimer’s disease: Comparison and associations from molecular to system level

Aging and Alzheimer’s disease: Comparison and associations from molecular to system level

Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease

Metabolomics in the Study of Alzheimer's Disease

Contact Info

Product

Resources

About